Literature DB >> 23610116

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.

Jennifer R Diamond1, Ravi Salgia, Marileila Varella-Garcia, Rajani Kanteti, Patricia M LoRusso, Jeffrey W Clark, Ling-Guo Xu, Keith Wilner, S Gail Eckhardt, Keith A Ching, Maruja E Lira, Eric F P M Schoenmakers, James G Christensen, D Ross Camidge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23610116      PMCID： PMC3661938          DOI： 10.1200/JCO.2012.46.4289

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  24 in total

1.  Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

Authors:  Todd M Pitts; Aik Choon Tan; Gillian N Kulikowski; John J Tentler; Amy M Brown; Sara A Flanigan; Stephen Leong; Christopher D Coldren; Fred R Hirsch; Marileila Varella-Garcia; Christopher Korch; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

Authors:  Joseph Paul Eder; Geoffrey I Shapiro; Leonard J Appleman; Andrew X Zhu; Dale Miles; Harold Keer; Belinda Cancilla; Felix Chu; Suzanne Hitchcock-Bryan; Laurie Sherman; Stewart McCallum; Elisabeth I Heath; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2010-05-14       Impact factor: 12.531

Review 4.  Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Authors:  Scott J Rodig; Geoffrey I Shapiro
Journal:  Curr Opin Investig Drugs       Date:  2010-12

5.  A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.

Authors:  Peter J Rosen; Christopher J Sweeney; Dorothy J Park; Darrin M Beaupre; Hongjie Deng; Ian M Leitch; Poornima Shubhakar; Min Zhu; Kelly S Oliner; Abraham Anderson; Lorrin K Yee
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

Review 6.  Targeting the HGF/Met signalling pathway in cancer.

Authors:  Fabiola Cecchi; Daniel C Rabe; Donald P Bottaro
Journal:  Eur J Cancer       Date:  2010-03-19       Impact factor: 9.162

Review 7.  Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Authors:  Joseph Paul Eder; George F Vande Woude; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

8.  Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

Authors:  Michael S Gordon; Christopher S Sweeney; David S Mendelson; S Gail Eckhardt; Abraham Anderson; Darrin M Beaupre; Daniel Branstetter; Teresa L Burgess; Angela Coxon; Hongjie Deng; Paula Kaplan-Lefko; Ian M Leitch; Kelly S Oliner; Lucy Yan; Min Zhu; Lia Gore
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

9.  Contemporary epidemiology of renal cell cancer.

Authors:  Wong-Ho Chow; Susan S Devesa
Journal:  Cancer J       Date:  2008 Sep-Oct       Impact factor: 3.360

10.  Ethnic differences and functional analysis of MET mutations in lung cancer.

Authors:  Soundararajan Krishnaswamy; Rajani Kanteti; Jonathan S Duke-Cohan; Sivakumar Loganathan; Wanqing Liu; Patrick C Ma; Martin Sattler; Patrick A Singleton; Nithya Ramnath; Federico Innocenti; Dan L Nicolae; Zheng Ouyang; Jie Liang; John Minna; Mark F Kozloff; Mark K Ferguson; Viswanathan Natarajan; Yi-Ching Wang; Joe G N Garcia; Everett E Vokes; Ravi Salgia
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531
View more
  10 in total

1.  First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.

Authors:  Anna Capasso; Stacey M Bagby; Kyrie L Dailey; Naomi Currimjee; Betelehem W Yacob; Anastasia Ionkina; Julie G Frank; Deog Joong Kim; Christina George; Young B Lee; Ely Benaim; Brian Gittleman; Sarah J Hartman; Aik Choon Tan; Jihye Kim; Todd M Pitts; S Gail Eckhardt; John J Tentler; Jennifer R Diamond
Journal:  Mol Cancer Ther       Date:  2019-09-05       Impact factor: 6.261

2.  Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.

Authors:  Sharad Sharma; Hang-Ping Yao; Yong-Qing Zhou; Jianwei Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Mol Oncol       Date:  2014-01-02       Impact factor: 6.603

3.  Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.

Authors:  Hongjuan Zhao; Rosalie Nolley; Andy M W Chan; Erinn B Rankin; Donna M Peehl
Journal:  Cancer Biol Ther       Date:  2016-08-11       Impact factor: 4.742

Review 4.  Advances in Renal Cell Carcinoma Drug Resistance Models.

Authors:  Yien Xiang; Ge Zheng; Jianfeng Zhong; Jiyao Sheng; Hanjiao Qin
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

Review 5.  The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.

Authors:  Rahul A Parikh; Peng Wang; Jan H Beumer; Edward Chu; Leonard J Appleman
Journal:  Onco Targets Ther       Date:  2014-06-11       Impact factor: 4.147

6.  Distinct brain responses to different inhibitions: Evidence from a modified Flanker Task.

Authors:  Liufang Xie; Maofan Ren; Bihua Cao; Fuhong Li
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

Review 7.  Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.

Authors:  Philippe Rochigneux; Jeanne Thomassin-Piana; Sophy Laibe; Serge Brunelle; Naji Salem; Bernard Escudier; Gilles Vassal; Gwenaelle Gravis
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430

8.  Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer.

Authors:  Zhang-Song Wu; Wa Ding; Jiajia Cai; Ghassan Bashir; Yu-Qing Li; Song Wu
Journal:  Onco Targets Ther       Date:  2019-10-03       Impact factor: 4.147

9.  Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion.

Authors:  Qing Ma; Lingping Kong; Diansheng Zhong
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

Review 10.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.